CytomX Therapeutics (CTMX) Balance Sheet: Assets & Liabilities

CytomX Therapeutics (CTMX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), CytomX Therapeutics reported total assets of $151.57M and total liabilities of $52.56M. Shareholders' equity was $99.01M. Total debt stood at $4.24M against $137.05M in cash and short-term investments, a net cash position of $132.81M. That puts debt-to-equity at 0.04.

CytomX Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for CytomX Therapeutics, Inc. (CTMX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	12.67	38.05	17.17	193.65	205.53	191.86	188.43	247.58	177.55
Short-Term Investments	124.39	62.57	157.34	0.00	99.70	124.26	107.72	188.55	196.56
Cash & Short-Term Investments	137.05	100.62	174.51	193.65	305.23	316.12	296.15	436.13	374.11
Accounts Receivable	2.01	3.10	3.43	35.99	0.79	0.80	0.01	0.10	10.14
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	4.86	3.58	5.00	7.47	4.29	7.10	7.18	18.50	8.70
Total Current Assets	143.92	107.31	182.94	237.10	310.30	324.01	303.34	445.48	388.60
Non-Current Assets
Property, Plant & Equipment (Net)	4.70	10.60	16.18	21.02	25.32	29.45	32.75	6.93	4.22
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.92	0.92
Goodwill	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
Intangible Assets	0.44	0.58	0.73	0.88	1.02	1.17	1.31	1.46	1.60
Other Non-Current Assets	1.56	1.09	1.00	0.94	1.82	3.09	2.93	0.24	0.96
Total Non-Current Assets	7.65	13.23	18.86	23.79	29.11	34.65	37.95	11.63	9.04
Total Assets	151.57	120.53	201.79	260.89	339.41	358.66	341.28	457.11	397.64
Current Liabilities
Accounts Payable	1.30	1.09	1.46	2.81	2.82	3.00	4.16	5.13	4.21
Short-Term Debt	4.24	5.15	4.59	4.08	3.62	3.20	2.81	0.00	0.00
Accrued Liabilities	14.20	12.34	17.60	24.45	34.24	19.86	-	-	-
Deferred Revenue	26.88	67.20	132.27	121.27	40.82	42.06	51.38	52.71	40.56
Other Current Liabilities	14.20	12.34	17.60	1.63	30.62	19.86	27.24	26.72	16.38
Total Current Liabilities	46.62	85.77	155.91	152.61	77.87	68.11	85.59	97.91	61.15
Non-Current Liabilities
Long-Term Debt	0.00	4.24	9.39	13.98	18.06	21.68	24.87	0.00	0.00
Deferred Tax Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.14	0.40
Other Non-Current Liabilities	5.94	4.12	3.89	180.06	0.00	0.00	0.85	3.05	1.90
Total Non-Current Liabilities	5.94	35.22	93.33	194.03	262.00	298.33	204.58	228.32	266.60
Total Liabilities	52.56	120.99	249.24	346.64	339.87	366.44	290.17	326.23	327.75
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-711.95	-691.58	-723.45	-722.88	-623.56	-507.69	-417.23	-314.98	-219.47
Accumulated Other Comprehensive Income	0.11	0.03	0.10	0.01	-0.24	-0.05	0.06	-0.09	-0.09
Additional Paid-in Capital	810.84	691.10	675.91	637.12	623.34	499.96	468.29	445.96	289.45
Shares Outstanding	170.19	80.10	67.31	66.23	65.39	-	-	-	-
Total Stockholders' Equity	99.01	-0.46	-47.45	-85.75	-0.46	-7.77	51.11	130.88	69.90
Total Liabilities & Equity	151.57	120.53	201.79	260.89	339.41	358.66	341.28	457.11	397.64

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About CytomX Therapeutics Balance Sheet

How much debt does CytomX Therapeutics have?

CytomX Therapeutics had total debt of $4.24M as of Dec 31, 2025, against $137.05M in cash and short-term investments. Its debt-to-equity ratio was 0.04. Total debt was $9.38M a year earlier.

What are CytomX Therapeutics's total assets?

CytomX Therapeutics reported total assets of $151.57M as of Dec 31, 2025, up 25.7% from $120.53M a year earlier. Total liabilities were $52.56M.

What is CytomX Therapeutics's shareholders' equity?

CytomX Therapeutics's shareholders' equity was $99.01M as of Dec 31, 2025, or about $0.58 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition